Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting.

ABSTRACT:

Background

This study aimed to compare the benefits and identify the best second-line treatment regimen for gemcitabine-refractory unresectable pancreatic cancers.

Patients and methods

This retrospective analysis included 144 patients with unresectable pancreatic cancer who underwent a gemcitabine-based regimen as the first-line treatment. 57, 37, and 50 patients received oxaliplatin-, irinotecan-based, and modified FOLFIRINOX (mFFX) regimens, respectively. The primary endpoint of this study was progression-free survival (PFS) and the secondary endpoints were overall survival (OS), response rate, and treatment-related toxicity.

Results

There were no significant differences in median PFS (mPFS) (4.6 months vs. 2.9 months, P = 0.627, HR = 1.128, 95%CI 0.693-1.836) and m

SUBMITTER: Wang Q 

PROVIDER: S-EPMC12291407 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature